Labetuzumab-SN-38: Interim Phase I data

Interim data from 11 patients with metastatic colorectal cancer in an open-label, dose-escalation, U.S. Phase I trial showed that 2, 4, 8 and 16 mg/kg doses of labetuzumab-SN-38 every 2 weeks were gen...